Thus, the CCDC6 deficiency, accompanied by the HR-DNA repair defects, determines sensitivity to PARP-inhibitors, in lung, colon and prostate cancer cells, as recently demonstrated [12, 16, 17]. This evidence concerns the gene CCDC6 and prostate cancer.